Company news
Gri Bio, Inc. (NASDAQ:GRI) news
Gri Bio, Inc. news releases on 6ix. Latest, Sep 28, 2026: GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Press releases & updates
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
September 28, 2026
GRI Bio Featured in "Why Now" On-Demand Video Webcast
August 27, 2026
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
August 24, 2026
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
June 18, 2026
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
April 8, 2026
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
February 17, 2026
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
February 5, 2026
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
February 4, 2026
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
January 28, 2026
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
January 26, 2026
GRI Bio Announces Reverse Stock Split
January 21, 2026
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
January 8, 2026
GRI Bio Announces Closing of $8.0 Million Public Offering
December 12, 2025
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
December 11, 2025
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
December 10, 2025
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
September 11, 2025
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 14, 2025
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
July 31, 2025
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
July 31, 2025
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
July 1, 2025
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
June 26, 2025
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
May 22, 2025
GRI Bio to Participate in the Virtual Investor Closing Bell Series
May 21, 2025
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
May 16, 2025
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
May 15, 2025
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
May 8, 2025
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
May 7, 2025
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
April 16, 2025
GRI Bio Announces Closing of $5.0 Million Public Offering
April 2, 2025
GRI Bio Announces Pricing of $5.0 Million Public Offering
April 1, 2025
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
April 1, 2025
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
March 31, 2025
GRI Bio Participates in a Virtual Investor CEO Connect Segment
March 18, 2025
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
March 17, 2025
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
March 11, 2025
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
GRI Bio : Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI 0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis Form 8 K
November 14, 2024
GRI Bio : Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 Form 8 K
October 24, 2024
GRI Bio : Announces Exercise of Warrants Form 8 K
October 20, 2024
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 15, 2023
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 2, 2021
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 22, 2021
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 11, 2021
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 8, 2021